(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide (Compound)

Description: A compound in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View (6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
	(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide Compound (Entity type)	Indication Knowledge Graph Relation (Entity type)	Bladder muscle dysfunction - overactive Disease or Phenotype (Entity type)
	(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Beta-3 adrenergic receptor Protein (Entity type)	EC50

(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide
Compound (Entity type)
Indication
Knowledge Graph Relation (Entity type)
Bladder muscle dysfunction - overactive
Disease or Phenotype (Entity type)

(6S)-N-[4-({(2S,5R)-5-[(R)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-alpha]pyrimidine-6-carboxamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
Beta-3 adrenergic receptor
Protein (Entity type)
EC50

DISPLAY PER PAGE

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
Loading results...

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.